177 related articles for article (PubMed ID: 31912911)
1. Cardiac failure in patients treated with azacitidine, a pyrimidine analogue: Case reports and disproportionality analyses in Vigibase.
Perino J; Mottal N; Bohbot Y; Servant V; Berroneau A; Poustis P; Fenaux P; Laribi K; Charbonnier A; Bilion E; Calmettes C; Bégaud B; Pigneux A; Milpied N; Miremont-Salamé G; Théophile H; Dimicoli-Salazar S
Br J Clin Pharmacol; 2020 May; 86(5):991-998. PubMed ID: 31912911
[TBL] [Abstract][Full Text] [Related]
2. Drug-induced liver injury in Switzerland: an analysis of drug-related hepatic disorders in the WHO pharmacovigilance database VigiBase from 2010 to 2020.
Ortland I; Mirjalili M; Kullak-Ublick GA; Peymani P
Swiss Med Wkly; 2021 May; 151():w20503. PubMed ID: 34000058
[TBL] [Abstract][Full Text] [Related]
3. Identification of cellular targets involved in cardiac failure caused by PKI in oncology: an approach combining pharmacovigilance and pharmacodynamics.
Patras de Campaigno E; Bondon-Guitton E; Laurent G; Montastruc F; Montastruc JL; Lapeyre-Mestre M; Despas F
Br J Clin Pharmacol; 2017 Jul; 83(7):1544-1555. PubMed ID: 28098949
[TBL] [Abstract][Full Text] [Related]
4. Adverse Drug Reaction Reporting in Africa and a Comparison of Individual Case Safety Report Characteristics Between Africa and the Rest of the World: Analyses of Spontaneous Reports in VigiBase®.
Ampadu HH; Hoekman J; de Bruin ML; Pal SN; Olsson S; Sartori D; Leufkens HG; Dodoo AN
Drug Saf; 2016 Apr; 39(4):335-45. PubMed ID: 26754924
[TBL] [Abstract][Full Text] [Related]
5. Incretin-based drugs and intestinal obstruction: A pharmacovigilance study.
Gudin B; Ladhari C; Robin P; Laroche ML; Babai S; Hillaire-Buys D; Faillie JL
Therapie; 2020; 75(6):641-647. PubMed ID: 32418731
[TBL] [Abstract][Full Text] [Related]
6. Cataracts and statins. A disproportionality analysis using data from VigiBase.
Macías Saint-Gerons D; Bosco Cortez F; Jiménez López G; Castro JL; Tabarés-Seisdedos R
Regul Toxicol Pharmacol; 2019 Dec; 109():104509. PubMed ID: 31669197
[TBL] [Abstract][Full Text] [Related]
7. Heart failure and atrial tachyarrhythmia on abiraterone: A pharmacovigilance study.
Bretagne M; Lebrun-Vignes B; Pariente A; Shaffer CM; Malouf GG; Dureau P; Potey C; Funck-Brentano C; Roden DM; Moslehi JJ; Salem JE
Arch Cardiovasc Dis; 2020 Jan; 113(1):9-21. PubMed ID: 31685432
[TBL] [Abstract][Full Text] [Related]
8. Differences in VigiBase® reporting of aminoglycoside and capreomycin-suspected ototoxicity during tuberculosis treatment.
Sagwa EL; Souverein PC; Ribeiro I; Leufkens HG; Mantel-Teeuwisse AK
Pharmacoepidemiol Drug Saf; 2017 Jan; 26(1):1-8. PubMed ID: 27868278
[TBL] [Abstract][Full Text] [Related]
9. Pharmacovigilance in ophthalmology in Switzerland: an analysis of the most frequently reported ocular adverse drug reactions within the last 25 years.
Karrer JE; Giovannoni L; Kullak-Ublick GA; Weiler S
Swiss Med Wkly; 2019 Jun; 149():w20085. PubMed ID: 31256417
[TBL] [Abstract][Full Text] [Related]
10. Cardiovascular Toxicities Associated With Ibrutinib.
Salem JE; Manouchehri A; Bretagne M; Lebrun-Vignes B; Groarke JD; Johnson DB; Yang T; Reddy NM; Funck-Brentano C; Brown JR; Roden DM; Moslehi JJ
J Am Coll Cardiol; 2019 Oct; 74(13):1667-1678. PubMed ID: 31558250
[TBL] [Abstract][Full Text] [Related]
11. Intravitreal Anti-VEGF Drugs and Signals of Dementia and Parkinson-Like Events: Analysis of the VigiBase Database of Spontaneous Reports.
Sultana J; Scondotto G; Cutroneo PM; Morgante F; Trifirò G
Front Pharmacol; 2020; 11():315. PubMed ID: 32226387
[TBL] [Abstract][Full Text] [Related]
12. Calcitonin gene-related peptide antagonists in pregnancy: a disproportionality analysis in VigiBase
Noseda R; Bedussi F; Gobbi C; Ceschi A; Zecca C
J Headache Pain; 2024 Jan; 25(1):10. PubMed ID: 38243189
[TBL] [Abstract][Full Text] [Related]
13. Can tramadol really induce hyponatraemia? A pharmacovigilance study.
de Canecaude C; Rousseau V; Chebane L; Lafaurie M; Durrieu G; Montastruc JL
Br J Clin Pharmacol; 2021 Feb; 87(2):683-686. PubMed ID: 32470196
[TBL] [Abstract][Full Text] [Related]
14. Drug induced stuttering: pharmacovigilance data.
Trenque T; Morel A; Trenque A; Azzouz B
Expert Opin Drug Saf; 2021 Mar; 20(3):373-378. PubMed ID: 33337944
[No Abstract] [Full Text] [Related]
15. Cardiovascular and gastrointestinal safety of selective cyclooxygenase-2 inhibitors: a case/non-case study.
Martin Arias LH; Martin Gonzalez A; Sanz Fadrique R; Salgueiro E; Sainz M
Int J Clin Pharm; 2018 Aug; 40(4):928-935. PubMed ID: 30066292
[TBL] [Abstract][Full Text] [Related]
16. Suspected adverse reactions reported for blood, blood components, and blood products in VigiBase.
Samukange WT; Lu TA; Souverein PC; Gardarsdottir H; Mantel-Teeuwisse AK
Transfusion; 2023 May; 63(5):982-992. PubMed ID: 36994873
[TBL] [Abstract][Full Text] [Related]
17. Identification of Substandard Medicines via Disproportionality Analysis of Individual Case Safety Reports.
Trippe ZA; Brendani B; Meier C; Lewis D
Drug Saf; 2017 Apr; 40(4):293-303. PubMed ID: 28130773
[TBL] [Abstract][Full Text] [Related]
18. Adverse Event Profiles of PARP Inhibitors: Analysis of Spontaneous Reports Submitted to FAERS.
Tian X; Chen L; Gai D; He S; Jiang X; Zhang N
Front Pharmacol; 2022; 13():851246. PubMed ID: 35401230
[No Abstract] [Full Text] [Related]
19. Investigating Overlap in Signals from EVDAS, FAERS, and VigiBase
Vogel U; van Stekelenborg J; Dreyfus B; Garg A; Habib M; Hosain R; Wisniewski A
Drug Saf; 2020 Apr; 43(4):351-362. PubMed ID: 32020559
[TBL] [Abstract][Full Text] [Related]
20. Drug-induced vitiligo: a case/non-case study in Vigibase
Anthony N; Bourneau-Martin D; Ghamrawi S; Lagarce L; Babin M; Briet M
Fundam Clin Pharmacol; 2020 Dec; 34(6):736-742. PubMed ID: 32246859
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
